Company Overview and News

1
Dalradian Announces Results of its 2018 Meeting of Shareholders

19h globenewswire
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") is pleased to announce the results of its 2018 annual meeting of shareholders (the “Meeting”) held today in Toronto, Ontario.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Dalradian files NI 43-101 technical report for the updated mineral resource statement for the Curraghinalt gold deposit

2018-06-22 globenewswire
TORONTO, June 22, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") reports that it has filed on SEDAR the National Instrument 43-101 technical report for its updated mineral resource statement for the Curraghinalt gold deposit in Northern Ireland. Highlights of the report were previously announced on May 10, 2018. Because this latest technical report supersedes any previous reports and renders them obsolete, the Company has removed the previous technical report (the 2016 Feasibility Study) from its website and marketing materials.
DRLDF DNA.WT.A DRRLF DALR DNA

33
Top Dalradian shareholder supports Orion Mine takeover offer

2018-06-21 reuters
TORONTO (Reuters) - M&G Investment Management, the biggest shareholder in Dalradian Resources Inc (DNA.TO), said on Thursday it was supportive of a friendly cash takeover offer for Dalradian from private equity group Orion Mine Finance.
DRLDF BLK DNA.WT.A DRRLF DALR DNA

33
Recommended Cash Offer by Orion Mine Finance to Acquire Dalradian Resources Inc.

2018-06-21 globenewswire
TORONTO, June 21, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) and Orion Mine Finance are pleased to announce that the Company and certain affiliates of Orion Mine Finance (collectively, “Orion”) have entered into a definitive arrangement agreement (the “Arrangement Agreement”), whereby Orion will acquire all of the issued and outstanding common shares of the Company (“Dalradian Shares”) by way of a statutory plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).
DRLDF BLK DNA.WT.A FPC OKSWF DRRLF OR OSKGF FPRGF BGMZF DALR DNA

1
Walkabout Resources share spike attracts ASX speeding ticket

2018-05-11 proactiveinvestors.com.au
Walkabout Resources Ltd’s (ASX:WKT) shares have been on a tear, rising from a close of 8.3 cents on Thursday to an intraday high of 10.5 cents today, prompting the ASX to issue a speeding ticket.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Dalradian announces a 46% increase in Measured & Indicated gold ounces and a 32% increase in Inferred gold ounces in new Mineral Resource Statement

2018-05-10 globenewswire
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) ("Dalradian" or the "Company") announces an updated mineral resource statement on the Curraghinalt gold deposit in Northern Ireland (“Mineral Resource Statement”), including a 46% increase in gold ounces contained in the Measured and Indicated (“M&I”) categories and a 32% increase in Inferred gold ounces compared to the 2016 resource.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Dalradian intersects 1.54 metres at 61.49 g/t gold from drilling at Curraghinalt

2018-05-01 globenewswire
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) is pleased to report results from 13 step-out drill holes and 30 infill drill holes at the Curraghinalt gold deposit in Northern Ireland.
DRLDF DNA.WT.A DRRLF DALR DNA

1
Walkabout Resources to fly survey over Northern Ireland cobalt-copper-silver targets

2018-04-11 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) will fly an airborne electromagnetic (EM) survey over target areas of the Slieve Gallion cobalt-copper-silver joint venture licence area in Northern Ireland.
DRLDF DNA.WT.A DRRLF WKT DALR DNA

1
Walkabout Resources set to unlock lithium, cobalt, gold and graphite opportunities

2018-03-27 proactiveinvestors.com.au
Walkabout Resources Ltd (ASX:WKT) is continuing to focus on lithium exploration in Namibia along with an active cobalt exploration program in Northern Ireland.
DRLDF DNA.WT.A LMI DRRLF WKT DALR DNA

1
Dalradian reports 2017 results with year-end cash of $138 million

2018-03-19 globenewswire
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Dalradian Resources Inc. (TSX:DNA) (AIM:DALR) (“Dalradian” or the “Company”) announces results for the three months and year ended December 31, 2017, including closing cash and cash equivalents of $138 million1.
DRLDF DNA.WT.A DRRLF DALR DNA

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 235499951